140 related articles for article (PubMed ID: 29932858)
21. [Predictive factors of invasion with initial diagnosis of ductal carcinoma in situ based on core biopsy].
Kósa C; Garami Z; Dinya T; Fülöp B
Magy Seb; 2012 Aug; 65(4):218-21. PubMed ID: 22940391
[TBL] [Abstract][Full Text] [Related]
22. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
23. Utility of intraoperative frozen section examination of sentinel lymph nodes in ductal carcinoma in situ of the breast.
Ballehaninna UK; Chamberlain RS
Clin Breast Cancer; 2013 Oct; 13(5):350-8. PubMed ID: 23791128
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component.
Wasserberg N; Morgenstern S; Schachter J; Fenig E; Lelcuk S; Gutman H
Arch Surg; 2002 Nov; 137(11):1249-52. PubMed ID: 12413311
[TBL] [Abstract][Full Text] [Related]
25. The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast.
van la Parra RF; Ernst MF; Barneveld PC; Broekman JM; Rutten MJ; Bosscha K
Eur J Surg Oncol; 2008 Jun; 34(6):631-5. PubMed ID: 17851019
[TBL] [Abstract][Full Text] [Related]
26. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.
Yen TW; Hunt KK; Ross MI; Mirza NQ; Babiera GV; Meric-Bernstam F; Singletary SE; Symmans WF; Giordano SH; Feig BW; Ames FC; Kuerer HM
J Am Coll Surg; 2005 Apr; 200(4):516-26. PubMed ID: 15804465
[TBL] [Abstract][Full Text] [Related]
27. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
[TBL] [Abstract][Full Text] [Related]
28. Can tumor-associated macrophages in ductal carcinoma in situ on biopsy predict invasive carcinoma on excision?
Hoskoppal D; Reisenbichler ES
Hum Pathol; 2018 Dec; 82():158-162. PubMed ID: 30067949
[TBL] [Abstract][Full Text] [Related]
29. Intracystic (encysted) papillary carcinoma of the breast: a clinical, pathological, and immunohistochemical study.
Leal C; Costa I; Fonseca D; Lopes P; Bento MJ; Lopes C
Hum Pathol; 1998 Oct; 29(10):1097-104. PubMed ID: 9781648
[TBL] [Abstract][Full Text] [Related]
30. Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ.
Maffuz A; Barroso-Bravo S; Nájera I; Zarco G; Alvarado-Cabrero I; Rodríguez-Cuevas SA
J Exp Clin Cancer Res; 2006 Jun; 25(2):223-7. PubMed ID: 16918134
[TBL] [Abstract][Full Text] [Related]
31. Ductal carcinoma in situ with distorting sclerosis on core biopsy may be predictive of upstaging on excision.
Walters LL; Pang JC; Zhao L; Jorns JM
Histopathology; 2015 Mar; 66(4):577-86. PubMed ID: 25231210
[TBL] [Abstract][Full Text] [Related]
32. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases.
Han JS; Molberg KH; Sarode V
Breast J; 2011; 17(3):223-9. PubMed ID: 21545433
[TBL] [Abstract][Full Text] [Related]
33. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases.
Goyal A; Douglas-Jones A; Monypenny I; Sweetland H; Stevens G; Mansel RE
Breast Cancer Res Treat; 2006 Aug; 98(3):311-4. PubMed ID: 16552627
[TBL] [Abstract][Full Text] [Related]
34. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
Renshaw AA; Gould EW
Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
[TBL] [Abstract][Full Text] [Related]
35. Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only.
Dillon MF; McDermott EW; Quinn CM; O'Doherty A; O'Higgins N; Hill AD
J Surg Oncol; 2006 Jun; 93(7):559-63. PubMed ID: 16705731
[TBL] [Abstract][Full Text] [Related]
36. The role of sentinel node biopsy in ductal carcinoma in situ of the breast.
Polom K; Murawa D; Wasiewicz J; Nowakowski W; Murawa P
Eur J Surg Oncol; 2009 Jan; 35(1):43-7. PubMed ID: 18723312
[TBL] [Abstract][Full Text] [Related]
37. Sentinel node biopsy in ductal carcinoma in situ patients.
Pendas S; Dauway E; Giuliano R; Ku N; Cox CE; Reintgen DS
Ann Surg Oncol; 2000; 7(1):15-20. PubMed ID: 10674443
[TBL] [Abstract][Full Text] [Related]
38. [Histological grading in ductal carcinoma in situ of the breast].
Xu W; Zhu X; Zhang T; Tu X; Shi D
Zhonghua Bing Li Xue Za Zhi; 1999 Oct; 28(5):331-3. PubMed ID: 11869542
[TBL] [Abstract][Full Text] [Related]
39. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases.
Yeung DK; Yang WT; Tse GM
Radiology; 2002 Oct; 225(1):190-7. PubMed ID: 12355004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
